Optimal use of biologics in Crohn’s disease
taking a long term view
In this 35-minute recorded webinar, Professor Lindsay talks about the progressive nature of Crohn’s Disease, the value of achieving mucosal healing in the long term, and the benefits and risks of available biologic options.
Topics covered during the online lecture:
01.05-03:52 - The benefits of achieving long term mucosal healing
03.53-12:10 - What is the right patient at the right time?
12:11-16:54 - Benefits and risks of using biologics
16.55-18:49 - Immunogenicity and long term complications
18.50-21:11 - Prolonged benefits
21.12-22:29 - Minimizing the risk of infections
22.30-28:13 - Monitoring patients
28.14-36:05 - Summary
Professor James Lindsay;
Professor of Inflammatory Bowel Disease, Barts and the London School of Medicine and Dentistry, Queen Mary University of London.
Professor James Lindsay is the Education Officer and a member of the Governing Board of the European Crohn’s and Colitis Organisation (ECCO).
He has chaired working groups for the ECCO consensus on the management of Crohn’s disease and ulcerative colitis. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology and is a member of the International Organisation of IBD (IOIBD).
Clas answers the following questions in the interview:
- Can you give us a better understanding of the types of patients you see and their unmet needs?
- What are the practical issues around treatment optimization?
- If the patient’s therapy is changed to Stelara®, when should their response be assessed?
- What are the options for patients in whom anti-TNF therapy is not or no longer suitable?
Dr. Clas-Göran af Björkesten;
Dr. Clas-Göran af Björkesten, Consultant in Gastroenterology, Helsinki University Hospital, Finland, joined ECCO congress in Copenhagen in March 2019. He kindly gave a short overview on the latest topics around Crohn’s disease covering patient unmet needs, treatment optimization and options available today for patients.
In his interview, Clas-Göran af Björkesten talks about challenges which are often related to the treatment of Crohn’s disease patients; limited amount of treatment options available and the fact that many of the patients have suffered from the disease long time and they might have difficult complications.
He also discusses about TDM (therapeutic drug monitoring) which offers the possibility of a more personalized treatment approach and optimization of therapy for Crohn´s disease.